Surface markers of hepatocellular cancer stem cells and their clinical potential

Neoplasma

Volumn 61, Issue 5, 2014, Pages 505-513

  Feng, D ^a   Wang, N ^a   Hu, J ^a,b   Li, W ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Cancer stem cells; CD133; CD44; CD90; EpCAM; Surface marker

Indexed keywords

ABC TRANSPORTER B5; ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CD133 ANTIGEN; CD24 ANTIGEN; CELL SURFACE MARKER; DELTA LIKE 1 HOMOLOG; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; MICROSOMAL AMINOPEPTIDASE; OV6 ANTIBODY; THY 1 ANTIGEN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

CANCER GROWTH; CANCER RECURRENCE; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL ISOLATION; CLINICAL FEATURE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; REVIEW; CHEMISTRY; LIVER TUMOR; PATHOLOGY; PROGNOSIS;

ANTIGENS, CD; ANTIGENS, CD44; ANTIGENS, NEOPLASM; ANTIGENS, THY-1; CELL ADHESION MOLECULES; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84907294839     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2014_061     Document Type: Review

References (86)

1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255. http://dx.doi.org/10.1016/S0140-6736(11)61347-0
2. El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2011; 365: 1118-1127. http://dx.doi.org/10.1056/NEJMra1001683
3. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008; 268: 1-9. http://dx.doi.org/10.1016/j.canlet.2008.03.048
4. Fulda S, Pervaiz S. Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 2010; 42: 31-38. http://dx.doi.org/10.1016/j.biocel.2009.06.010
5. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-3988. http://dx.doi.org/10.1073/pnas.0530291100
6. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV et al. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008; 10: R10. http://dx.doi.org/10.1186/bcr1855
7. Ma S, Chan KW, Hu L, Lee TK, Wo JY et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007; 132: 2542-2556. http://dx.doi.org/10.1053/j.gastro.2007.04.025
8. Yin S, Li J, Hu C, Chen X, Yao M et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-1450. http://dx.doi.org/10.1002/ijc.22476
9. Ma S, Chan KW, Lee TK, Tang KH, Wo JY et al. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-1153. http://dx.doi.org/10.1158/1541-7786.MCR-08-0035
10. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-115. http://dx.doi.org/10.1038/nature05384
11. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-10163. http://dx.doi.org/10.1073/pnas.0703478104
12. O‘brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 2007; 445: 106-110. http://dx.doi.org/10.1038/nature05372
13. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514. http://dx.doi.org/10.1038/sj.cdd.4402283
14. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005; 121: 823-835. http://dx.doi.org/10.1016/j.cell.2005.03.032
15. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037. http://dx.doi.org/10.1158/0008-5472.CAN-06-2030
16. Rasheed Z, Wang Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010. http://dx.doi.org/10.3791/2169
17. Huff CA, Matsui W. Multiple Myeloma Cancer stem Cells. J Clin Oncol 2008; 26: 2895-2900. http://dx.doi.org/10.1200/JCO.2007.15.8428
18. Ji J, Wang XW. Clinical implications of cancer stem cell biology in hepatocellular carcinoma. Semin Oncol 2012; 39: 461-472. http://dx.doi.org/10.1053/j.seminoncol.2012.05.011
19. Szilvassy S, Humphries R, Lansdorp P, Eaves Aeaves C. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 8736-8740. http://dx.doi.org/10.1073/pnas.87.22.8736
20. Graham SM. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99.
21. Xu X, Liu RF, Zhang X, Huang LY, Chen F et al. DLK1 as a potential target against cancer stem/progenitor cells of hepatocellular carcinoma. Mol Cancer Ther 2012; 11: 629-638. http://dx.doi.org/10.1158/1535-7163.MCT-11-0531
22. Yamashita T, Ji J, Budhu A, Forgues M, Yang W et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-1024. http://dx.doi.org/10.1053/j.gastro.2008.12.004
23. Lee TK, Castilho A, Cheung VC, Tang kh, MA S et al. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011; 9: 50-63. http://dx.doi.org/10.1016/j.stem.2011.06.005
24. Sukowati CH, Anfuso B, Torre G, Francalanci P, Croce LS et al. The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An and Study. PLoS One 2013; 8: e76830. http://dx.doi.org/10.1371/journal.pone.0076830
25. Chiba T, Kamiya A, Yokosuka Oiwama A. Cancer stem cells in hepatocellular carcinoma: Recent progress and perspective. Cancer Lett 2009; 286: 145-153. http://dx.doi.org/10.1016/j.canlet.2009.04.027
26. Ward Rjdirks PB. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol 2007; 2: 175-189. http://dx.doi.org/10.1146/annurev. pathol.2.010506.091847
27. Dalerba P, Cho Rwclarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.http://dx.doi.org/10.1146/annurev.med.58.062105.204854
28. Ailles le, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18: 460-466. http://dx.doi.org/10.1016/j.copbio.2007.10.007
29. Tong CM, Ma Sguan XY. Biology of hepatic cancer stem cells. J Gastroenterol Hepatol 2011; 26: 1229-1237. http://dx.doi.org/10.1111/j.1440-1746.2011.06762.x
30. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183: 1797-1806. http://dx.doi.org/10.1084/jem.183.4.1797
31. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006; 44: 240-251. http://dx.doi.org/10.1002/hep.21227
32. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001; 7: 1028-1034. http://dx.doi.org/10.1038/nm0901-1028
33. Shimano K, Satake M, Okaya A, Kitanaka J, KITANAKA N et al. Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol 2003; 163: 3-9. http://dx.doi.org/10.1016/S0002-9440(10)63624-3
34. Montanaro F, Liadaki K, Schienda J, Flint A, Gussoni E et al. Demystifying SP cell purification: viability, yield, and phenotype are defined by isolation parameters. Exp Cell Res 2004; 298: 144-154. http://dx.doi.org/10.1016/j.yexcr.2004.04.010
35. Challen GA, Little MH. A side order of stem cells: the SP phenotype. Stem Cells 2006; 24: 3-12. http://dx.doi.org/10.1634/stemcells.2005-0116
36. Xu Y, Xie Y, Wang X, Chen X, Liu Q et al. Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs. Oncol Rep 2013.
37. Sladek NE. Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol 2003; 17: 7-23. http://dx.doi.org/10.1002/jbt.10057
38. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567. http://dx.doi.org/10.1016/j.stem.2007.08.014
39. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, OGAWA M et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-5012.
40. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S et al. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000; 275: 5512-5520. http://dx.doi.org/10.1074/jbc.275.8.5512
41. Grosse-Gehling P, Fargeas CA, Dittfeld C, Garbe Y, Alison MR et al. CD133 as a biomarker for putative cancer stem cells in solid tumors: limitations, problems and challenges. J Pathol 2013; 229: 355-378. http://dx.doi.org/10.1002/path.4086
42. Wang S, Xu ZY, Wang LF, Su W. CD133+ cancer stem cells in lung cancer. Front Biosci (Landmark Ed) 2013; 18: 447-453. http://dx.doi.org/10.2741/4113
43. Janikova M, Skarda J, Dziechciarkova M, Radova L, Chmelova J et al. Identification of CD133+/nestin+ putative cancer stem cells in non-small cell lung cancer. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2010; 154: 321-326. http://dx.doi.org/10.5507/bp.2010.048
44. Cui F, Wang J, Chen Dchen YJ. CD133 is a temporary marker of cancer stem cells in small cell lung cancer, but not in non-small cell lung cancer. Oncol Rep 2011; 25: 701-708.
45. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 2009; 106: 16281-16286. http://dx.doi.org/10.1073/pnas.0905653106
46. Hilbe W, Dirnhofer S, Oberwasserlechner F, Schmid T, Gunsilius E et al. CD133 positive endothelial progenitor cells contribute to the tumor vasculature in non-small cell lung cancer. J Clin Pathol 2004; 57: 965-969. http://dx.doi.org/10.1136/jcp.2004.016444
47. Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW et al. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. J Surg Oncol 2013; 107: 799-806. http://dx.doi.org/10.1002/jso.23337
48. Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T et al. Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res 2010; 30: 2453-2457.
49. Hori Y. Prominin-1 (CD133) Reveals New Faces of Pancreatic Progenitor Cells and Cancer Stem Cells: Current Knowledge and Therapeutic Perspectives. Adv Exp Med Biol 2013; 777: 185-196. http://dx.doi.org/10.1007/978-1-4614-5894-4_12
50. Wang D, Zhu H, Zhu Y, Liu Y, Shen H et al. CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer. Acta Histochem 2013; 115: 349-356. http://dx.doi.org/10.1016/j.acthis.2012.09.007
51. Lee HJ, You DD, Choi DW, Choi YS, Kim SJ et al. Significance of CD133 as a cancer stem cell markers focusing on the tumorigenicity of pancreatic cancer cell lines. J Korean Surg Soc 2011; 81: 263-270. http://dx.doi.org/10.4174/jkss.2011.81.4.263
52. Chen KL, Pan F, Jiang H, Chen JF, Pei L et al. Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin Exp Metastasis 2011; 28: 751-763. http://dx.doi.org/10.1007/s10585-011-9407-7
53. Feng HL, Liu YQ, Yang LJ, Bian XC, Yang ZL et al. Expression of CD133 correlates with differentiation of human colon cancer cells. Cancer Biol Ther 2010; 9: 216-223. http://dx.doi.org/10.4161/cbt.9.3.10664
54. Puglisi MA, Sgambato A, Saulnier N, Rafanelli F, Barba M et al. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 2009; 13 Suppl 1: 55-62.
55. Haraguchi N, Ohkuma M, Sakashita H, Matsuzaki S, Tanaka F et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-2933. http://dx.doi.org/10.1245/s10434-008-0074-0
56. Lan X, Wu YZ, Wang Y, Wu FR, Zang CB et al. CD133 silencing inhibits stemness properties and enhances chemoradiosensitivity in CD133-positive liver cancer stem cells. Int J Mol Med 2013; 31: 315-324.
57. Piao LS, Hur W, Kim TK, Hong SW, Kim SW et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012; 315: 129-137. http://dx.doi.org/10.1016/j.canlet.2011.10.012
58. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T et al. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-824. http://dx.doi.org/10.1016/j.bbrc.2006.10.128
59. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS et al. miR- 130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 2010; 7: 694-707. http://dx.doi.org/10.1016/j.stem.2010.11.010
60. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A et al. CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 2009; 205: 524-533. http://dx.doi.org/10.1016/j.prp.2009.01.008
61. Huang lrhsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res 1995; 55: 4717-4721.
62. Van Weering DH, Baas Pdbos JL. A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 1993; 3: 100-106. http://dx.doi.org/10.1101/gr.3.2.100
63. Harn HJ, Ho LI, Yu CP, Wang MW, Lee HS et al. The variant mRNA isoform of human metastasis gene (CD44V) detected in the cell lines of human hepatocellular carcinoma. Biochem Mol Biol Int 1994; 32: 233-238.
64. Kon J, Ooe H, Oshima H, Kikkawa Ymitaka T. Expression of CD44 in rat hepatic progenitor cells. J Hepatol 2006; 45: 90-98. http://dx.doi.org/10.1016/j.jhep.2006.01.029
65. Cogliati B, Aloia TP, Bosch RV, Alves VA, Hernandez- Blazquez FJ et al. Identification of hepatic stem/progenitor cells in canine hepatocellular and cholangiocellular carcinoma. Vet Comp Oncol 2010; 8: 112-121. http://dx.doi.org/10.1111/j.1476-5829.2010.00210.x
66. Zhu Z, Hao X, Yan M, Yao M, Ge C et al. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer 2010; 126: 2067-2078.
67. Rege TA, Hagood JS. Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 2006; 20: 1045-1054. http://dx.doi.org/10.1096/fj.05-5460rev
68. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166. http://dx.doi.org/10.1016/j.ccr.2008.01.013
69. Yang ZF, Ngai P, Ho DW, Yu WC, Ng MN et al. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 2008; 47: 919-928. http://dx.doi.org/10.1002/hep.22082
70. Hashida H, Takabayashi A, Kanai M, Adachi M, Kondo K et al. Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 2002; 122: 376-386. http://dx.doi.org/10.1053/gast.2002.31095
71. Liu LL, Fu D, Ma Yshen XZ. The power and the promise of liver cancer stem cell markers. Stem Cells Dev 2011; 20: 2023-2030. http://dx.doi.org/10.1089/scd.2011.0012
72. Petrovic N, Schacke W, Gahagan JR, O‘conor CA, Winnicka B et al. CD13/APN regulates endothelial invasion and filopodia formation. Blood 2007; 110: 142-150. http://dx.doi.org/10.1182/blood-2006-02-002931
73. Christ B, Stock Pdollinger MM. CD13: Waving the flag for a novel cancer stem cell target. Hepatology 2011; 53: 1388-1390. http://dx.doi.org/10.1002/hep.24222
74. Nagano H, Ishii H, Marubashi S, Haraguchi N, Eguchi H et al. Novel therapeutic target for cancer stem cells in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2012; 19: 600-605. http://dx.doi.org/10.1007/s00534-012-0543-5
75. De Boer CJ, Van Krieken JH, Janssen-Van Rhijn Cmlitvinov SV. Expression of Ep-CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 1999; 188: 201-206. http://dx.doi.org/10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8
76. Choo AB, Tan HL, Ang SN, Fong WJ, Chin A et al. Selection against undifferentiated human embryonic stem cells by a cytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells 2008; 26: 1454-1463. http://dx.doi.org/10.1634/stemcells.2007-0576
77. Chen Y, Yu D, Zhang H, He H, Zhang C et al. CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 2012; 8: 992-1004. http://dx.doi.org/10.7150/ijbs.4454
78. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatology 2013; 57: 1484-1497. http://dx.doi.org/10.1002/hep.26168
79. Lee TK, Cheung Vcng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. Cancer Lett 2012.
80. Roskams T, De Vos R, Van Eyken P, Myazaki H, Van Damme B et al. Hepatic OV-6 expression in human liver disease and rat experiments: evidence for hepatic progenitor cells in man. J Hepatol 1998; 29: 455-463. http://dx.doi.org/10.1016/S0168-8278(98)80065-2
81. Yang W, Yan HX, Chen L, Liu Q, He YQ et al. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 2008; 68: 4287-4295. http://dx.doi.org/10.1158/0008-5472.CAN-07-6691
82. Yang W, Wang C, Lin Y, Liu Q, Yu LX et al. OV6(+) tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma. J Hepatol 2012; 57: 613-620. http://dx.doi.org/10.1016/j.jhep.2012.04.024
83. Tanimizu N, Nishikawa M, Saito H, Tsujimura Tmiyajima A. Isolation of hepatoblasts based on the expression of Dlk/Pref-1. J Cell Sci 2003; 116: 1775-1786. http://dx.doi.org/10.1242/jcs.00388
84. Huang J, Zhang X, Zhang M, Zhu JD, Zhang YL et al. Up-regulation of DLK1 as an imprinted gene could contribute to human hepatocellular carcinoma. Carcinogenesis 2007; 28: 1094-1103. http://dx.doi.org/10.1093/carcin/bgl215
85. Yamashita T, Forgues M, Wang W, Kim JW, YE Q et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-1461. http://dx.doi.org/10.1158/0008-5472.CAN-07-6013
86. Bentivegna A, Conconi D, Panzeri E, Sala E, Bovo G et al. Biological heterogeneity of putative bladder cancer stem-like cell populations from human bladder transitional cell carcinoma samples. Cancer Sci 2010; 101: 416-424. http://dx.doi.org/10.1111/j.1349-7006.2009.01414.x